Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07029581 · ClinicalTrials.gov registry record · Phase 2
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
A Phase 2 study of Lewy Body Dementia Psychosis, sponsored by ACADIA Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 180
- Enrollment target
- 20
- Study locations
NCT07029581: Recruiting Phase 2 study of Lewy Body Dementia Psychosis, sponsored by ACADIA Pharmaceuticals.
NCT07029581 is a Phase 2 study of Lewy Body Dementia Psychosis that is actively recruiting participants, run by ACADIA Pharmaceuticals. The registered enrollment target is 180 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07029581, a Phase 2 study of Lewy Body Dementia Psychosis, is actively recruiting participants, sponsored by ACADIA Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 180 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
Primary Outcome
Change from Baseline in Scale for the Assessment of Positive Symptoms- Lewy Body Dementia Psychosis (SAPS-LBDP) total score at Week 6
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ACP-204
Study Locations (20)
Florida
- Humanity Clinical Research, Corp - Aventura
- Parkinson's Disease and Movement Disorders Center of Boca Raton - Boca Raton
- K2 Medical Research Winter Garden LLC - Clermont
- K2 Summit Research - Lady Lake
- Neurology Associates, P. A. - Maitland
- Homestead Associates in Research Inc - Miami
- Premier Clinical Research Institute, Inc. - Miami
- Advanced Clinical Research Network, Corp - Miami
- MediClear Medical & Research Center, Inc. - Miami
- Health Synergy Clinical Research, LLC - West Palm Beach
Texas
- Horizon Clinical Research Group - Cypress
- The University of Texas Health Science Center San Antonio - San Antonio
California
- ATP Clinical Research Inc. - Irvine
Hawaii
- Hawaii Pacific Neuroscience - Honolulu
Kansas
- University of Kansas Medical Center Research Institute Inc. - Kansas City
New York
- Parkinson's Disease and Movement Disorders Center of Boca Raton d/b/a Parkinson's Research Center of America-Long Island - Commack
North Carolina
- UNC Hospitals - Chapel Hill
Ohio
- The Ohio State University, Energy Advancement and Innovation Center - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 180 participants |
| Start Date | 2025-08-06 |
| Est. Completion | 2028-03 |
| Phase | Phase 2 |
What NCT07029581 shows while recruiting
NCT07029581 is an interventional study that assigns participants to a tested intervention. The registered 180 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (35% higher).
The record links to 1 condition, with Lewy Body Dementia Psychosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07029581 names 20 study sites across 10 states, led by Florida, Texas, California.
Frequently Asked Questions
What is clinical trial NCT07029581 about?
NCT07029581 is a clinical study titled "Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis". Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.
What is the current status of trial NCT07029581?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 180 participants. The study started on 2025-08-06. Estimated completion is 2028-03.
What conditions does trial NCT07029581 study?
This clinical trial studies the following conditions: Lewy Body Dementia Psychosis.
What interventions are being tested in trial NCT07029581?
The interventions under investigation include: Placebo (DRUG), ACP-204 (DRUG).
Who is sponsoring clinical trial NCT07029581?
This trial is sponsored by ACADIA Pharmaceuticals, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07029581 being conducted?
This trial has 20 study locations across California, Florida, Hawaii, Kansas, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07029581's enrollment target sits among peer trials
180 365th of 2000 higher than 1,610 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01558804 · 180 participants
GRoup A StrePtococcus
- NCT02932176 · 180 participants
Machine Learning for Handheld Vascular Studies
- NCT03384563 · 180 participants · Phase 4
Effect of Dexmedetomidine on the Minimum Alveolar Concentration of Sevoflurane
- NCT03423628 · 180 participants · Phase 1
A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI